Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:3.1.6.1 (
sulfatase
)
3,205
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
The activities of arylsulfatases A and B were determined in human primary and secondary tumor tissues (total, 53 cases) of various histological types. Significantly higher activities of these sulfatases were found in almost all the primary lung carcinomas as compared to their corresponding uninvolved tissues. No significant correlation was demonstrated between the enzyme activities and histological figures (stroma amounts, etc.).
Lung adenocarcinoma
and squamous cell carcinoma showed the presence of an additional
arylsulfatase
component (B1) which was not detected in normal human lung. The tumor
arylsulfatase
B1 had an isoelectric point (pI) of 6.7 and was clearly distinguished from
arylsulfatase A
(pI 4.9) and
arylsulfatase B
(pI 9.1 to 9.2) in normal lung and lung tumor. The tumor B1 enzyme was demonstrated to be most probably an isoenzyme of
arylsulfatase B
, since this unusual enzyme was indistinguishable from
arylsulfatase B
in terms of Ag+ inhibition; its kinetic parameters of Km for p-nitrocatechol sulfate, which was 2.9 mM with B1; optimum pH of 6.3 for B1; heat stability; and substrate specificity for three synthetic and two physiological substrates.
...
PMID:Elevated activities and properties of arylsulfatases A and B and B-variant in human lung tumors. 743 63